The Swiss government wants to sell the 5.3 million doses it had already paid for, according to an article in NZZ am Sonntag.
“We are currently considering selling on the material” said Nora Kronig, deputy director of the Federal Office of Public Health.
NZZ claims the decision was made because “AstraZeneca's vaccine has a bad reputation”.
“In the current situation, Switzerland is not dependent on the the vaccines from AstraZeneca”, said Kronig.
Originally, the AstraZeneca vaccine was expected to make up around one seventh of the total vaccine doses in Switzerland’s entire vaccine drive.
However, at the beginning of February, the regulatory agency Swissmedic said that “the data currently available do not point to a positive decision regarding benefits and risks” of this vaccine.
Vaccines from four other manufacturers have been approved for use in Switzerland. They are Pfizer/BioNtech, Moderna, Curevac , and Novavax.
So far only two vaccines have been administered in Switzerland: those from Pfizer/BioNtech and Moderna.
There have so far been no indications as to who would be the likely recipient of the 5.3 million doses, or under what circumstances and conditions the sale would be made.